Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.85 |
| ▸ | RAB9A | P51151 | 1/20 | 0.85 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.65 |
| ▸ | CTDSP1 | Q9GZU7 | 2/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.62 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.61 |
| ▸ | USP2 | O75604 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.61 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.60 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.59 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.59 |
| ▸ | HRH1 | P35367 | 1/20 | 0.59 |
| ▸ | HTR2B | P41595 | 1/20 | 0.59 |
| ▸ | GRM5 | P41594 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23573449 | 0.95 | NPC1 (0.78) | NPC1RAB9ACYP2C19CTDSP1TDP1 | |
| SCHEMBL23573447 | 0.95 | NPC1 (0.78) | NPC1RAB9ACYP2C19CTDSP1TDP1 | |
| SCHEMBL16573964 | 0.94 | NPC1 (0.76) | NPC1RAB9ACYP2C19CTDSP1TDP1 | |
| SCHEMBL14460307 | 0.93 | RAB9A (0.97) | NPC1RAB9ACYP2C19CTDSP1TDP1 | |
| SCHEMBL14198233 | 0.92 | SMYD3 (0.74) | NPC1RAB9ACYP2C19CTDSP1TDP1 | |
| SCHEMBL5666371 | 0.92 | RAB9A (1.00) | NPC1RAB9ACYP2C19CTDSP1TDP1 | |
| SCHEMBL13485379 | 0.89 | NPC1 (0.74) | NPC1RAB9ACYP2C19CTDSP1TDP1 | |
| SCHEMBL279972 | 0.89 | NPC1 (0.74) | NPC1RAB9ACYP2C19CTDSP1TDP1 | |
| SCHEMBL13959947 | 0.88 | NPC1 (0.72) | NPC1RAB9ACYP2C19CTDSP1TDP1 | |
| Hydrochloric Acid SCHEMBL28155978 | 0.88 | NPC1 (0.72) | NPC1RAB9ACYP2C19CTDSP1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501830-B1 | 7-ARYL-3,9-DIAZABICYCLO[3.3.1]NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | ACTELION PHARMACEUTICALS LTD (CH) | 2011-10-05 | — | — | EP | claimed |
| EP-1620403-B1 | NOVEL 3,4-DISUBSTITUTED 1,2,3,6-TETRAHYDROPYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2007-11-28 | — | — | EP | claimed |
| WO-2024044778-A2 | NOVEL MODULATORS OF FSHR AND USES THEREOF | CELMATIX INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| WO-2024009283-A1 | AT2 ANTAGONISTS FOR NON-ADDICTIVE PAIN RELIEF | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2024-01-11 | — | — | WO | disclosed |
| CN-115710287-B | Ring-opening boronation reaction method for cyclopropane compound under no metal catalysis | 中国科学院兰州化学物理研究所 | 2024-01-09 | — | — | CN | disclosed |
| US-11858907-B2 | Kinase modulators | RHIZEN PHARMACEUTICALS AG (CH) | 2024-01-02 | — | — | US | disclosed |
| US-20230303586-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2023-09-28 | — | — | US | disclosed |
| CN-115710287-A | Ring-opening boronization reaction method of cyclopropane compound under condition of no metal catalysis | 中国科学院兰州化学物理研究所 | 2023-02-24 | — | — | CN | disclosed |
| US-11377444-B2 | Pyridopyrimidine compounds acting as mTORC 1/2 dual inhibitors | MEDSHINE DISCOVERY INC. (CN) | 2022-07-05 | — | — | US | disclosed |
| EP-3218375-B1 | SUBSTITUTED PYRROLOPYRDINES AS INHIBITORS OF BROMODOMAIN | GENENTECH INC (US) | 2022-04-27 | — | — | EP | disclosed |
| US-20200339568-A1 | PYRIDOPYRIMIDINE COMPOUNDS ACTING AS MTORC 1/2 DOUBLE-KINASE INHIBITORS | MEDSHINE DISCOVERY INC. (CN) | 2020-10-29 | — | — | US | disclosed |
| US-20090137583-A1 | 2-AMINOQUINAZOLINE DERIVATIVES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-05-28 | — | — | US | disclosed |
| EP-2060575-A1 | Dihydrothienopyrimidines and their use in treating inflammatory diseases | Boehringer Ingelheim International GmbH (DE) | 2009-05-20 | — | — | EP | disclosed |
| US-7473783-B2 | Bicyclic pyrazolo protein kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2009-01-06 | — | — | US | disclosed |
| US-20080319033-A1 | 3-{3-[5-(4-acetylphenyl)-4-methylthiazol-2-yl]-ureido}-N-tert-butylpropionamide, exhibiting phosphatidylinositol 3-kinase inhibitory activity and used for treating respiratory system disorders, such as asthma | NOVARTIS AG | 2008-12-25 | — | — | US | disclosed |
| US-20080319033-A1 | 3-{3-[5-(4-acetylphenyl)-4-methylthiazol-2-yl]-ureido}-N-tert-butylpropionamide, exhibiting phosphatidylinositol 3-kinase inhibitory activity and used for treating respiratory system disorders, such as asthma | NOVARTIS AG | 2008-12-25 | — | — | US | disclosed |
| EP-1878727-A1 | 2-AMINOQUINAZOLINE DERIVATIVES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2008-01-16 | — | — | EP | disclosed |
| WO-2007068473-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2007-06-21 | — | — | WO | disclosed |
| US-20060178375-A1 | Heteroaryloxy nitrogenous saturated heterocyclic derivative | MSD K.K. (JP) | 2006-08-10 | — | — | US | disclosed |
| EP-1642898-A1 | HETEROARYLOXY NITROGENOUS SATURATED HETEROCYCLIC DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-04-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11377444-B2 | Pyridopyrimidine compounds acting as mTORC 1/2 dual inhibitors | MTOR, RICTOR, MAPKAP1 | NPC1 2647/4885RAB9A 2184/4885CYP2C19 285/4885 |
| US-20090137583-A1 | 2-AMINOQUINAZOLINE DERIVATIVES | SLC7A1, SLC38A7, PRMT7 | NPC1 2386/4885RAB9A 112/4885CYP2C19 342/4885 |
| US-20200339568-A1 | PYRIDOPYRIMIDINE COMPOUNDS ACTING AS MTORC 1/2 DOUBLE-KINASE INHIBITORS | MTOR, RICTOR, MAPKAP1 | NPC1 2963/4885RAB9A 2013/4885CYP2C19 485/4885 |
| US-20060178375-A1 | Heteroaryloxy nitrogenous saturated heterocyclic derivative | HRH3, HRH4, HCRTR2 | NPC1 1159/4885RAB9A 2274/4885CYP2C19 746/4885 |
| US-11858907-B2 | Kinase modulators | RPS6KA1, RPS6KA2, PRKAR2A | NPC1 2061/4885RAB9A 1518/4885CYP2C19 3477/4885 |
| US-20080319033-A1 | 3-{3-[5-(4-acetylphenyl)-4-methylthiazol-2-yl]-ureido}-N-tert-butylpropionamide, exhibiting phosphatidylinositol 3-kinase inhibitory activity and used for treating respiratory system disorders, such as asthma | AKT3, PIK3R3, PIK3CD | NPC1 3385/4885RAB9A 1515/4885CYP2C19 2458/4885 |
| US-20230303586-A1 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | NPC1 3306/4885RAB9A 33/4885CYP2C19 3772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.